1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------------------------------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report : August 8, 2001
Commission File No: 0-10824
GENOME THERAPEUTICS CORP.
------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
MASSACHUSETTS 0-10824 04-2297484
------------------------------- ------------------------ -------------------
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
100 BEAVER STREET, WALTHAM, MASSACHUSETTS 02453
---------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
Registrant's telephone number: (781) 398-2300
--------------
Not Applicable
------------------------------------------------------------
Former name or former address, if changed since last report)
2
ITEM 8. CHANGE IN FISCAL YEAR
On July 24, 2001 the Board of Directors of Genome Therapeutics Corp.
("Genome") approved a change of Genome's fiscal year end from August 31 to
December 31, as of the fiscal year ended December 31, 2000. A transition report
on Form 10-Q covering the transition period from September 1, 2000 through
December 31, 2000, will be filed with the Securities and Exchange Commission by
no later than September 7, 2001; this filing will include financial statements
restated to provide financial information for the four months ended December 31,
2000 and 1999.
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENOME THERAPEUTICS CORP
By: /s/ Stephen Cohen
-------------------------------
Stephen Cohen,
Senior Vice President - Finance
and Chief Financial Officer
Date: August 8, 2001